Trials / Completed
CompletedNCT00673608
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasirox) (The MILE Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the change in cardiac iron load over a 53 week period measured by MRI in 2 cohorts of patients
Conditions
- Hemoglobinopathies
- Myelodysplastic Syndromes
- Other Inherited or Acquired Anaemia
- MPD Syndrome
- Diamond-Blackfan Anemia
- Other Rare Anaemias
- Transfusional Iron Overload
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | deferasirox | Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2008-05-07
- Last updated
- 2017-02-23
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT00673608. Inclusion in this directory is not an endorsement.